1446328-06-8

Basic information

• Product Name: 7-(4-methylpiperazin-1-yl)-3-(1-phenyl-1H-pyrazol-3-yl)-2H-chromen-2-one
• Synonyms: 7-(4-methylpiperazin-1-yl)-3-(1-phenyl-1H-pyrazol-3-yl)-2H-chromen-2-one
• CAS NO: 1446328-06-8
• Molecular Weight: 386.453
• Mol File: 1446328-06-8.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 7-(4-methylpiperazin-1-yl)-3-(1-phenyl-1H-pyrazol-3-yl)-2H-chromen-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 7-(4-methylpiperazin-1-yl)-3-(1-phenyl-1H-pyrazol-3-yl)-2H-chromen-2-one(1446328-06-8)
• EPA Substance Registry System: 7-(4-methylpiperazin-1-yl)-3-(1-phenyl-1H-pyrazol-3-yl)-2H-chromen-2-one(1446328-06-8)

Safety Data

• Hazardous Substances Data: 1446328-06-8(Hazardous Substances Data)

Upstream product

• 1446332-69-9 tert-butyl 4-(4-formyl-3-hydroxyphenyl)piperazine-1-carboxylate 
• 348-28-7 4-fluoro-2-hydroxybenzaldehyde 
• 50-00-0 formaldehyd 
• 1446333-26-1 3-(1-phenyl-1H-pyrazol-3-yl)-7-(piperazin-1-yl)-2H-chromen-2-one 
• 1446333-24-9 tert-butyl 4-(2-oxo-3-(1-phenyl-1H-pyrazol-3-yl)-2H-chromen-7-yl)piperazine-1-carboxylate 
• 1446333-20-5 tert-butyl 4-(2-oxo-3-(1H-pyrazol-3-yl)-2H-chromen-7-yl)piperazine-1-carboxylate 
• 1446333-18-1 tert-butyl 4-(3-acetyl-2-oxo-2H-chromen-7-yl)piperazine-1-carboxylate 

Relevant articles and documents

Compounds for treating spinal muscular atrophy

Provided herein are compounds, compositions thereof and uses therewith for treating spinal muscular atrophy. In a specific embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN2 into mRNA that is transcribed from the SMN2 gene. In another specific embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN1 into mRNA that is transcribed from the SMN1 gene. In yet another embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN1 and SMN2 into mRNA that is transcribed from the SMN1 and SMN2 genes, respectively.